Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LSS | P48449 | 9/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.45 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.45 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.45 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6402854 | 0.95 | LSS (0.48) | LSSLMNAMAPTTP53TAS1R3 | |
| SCHEMBL6399162 | 0.89 | LMNA (0.53) | LSSLMNAMAPTTP53TAS1R3 | |
| SCHEMBL6397754 | 0.88 | MAPT (0.53) | LSSMAPTNOTUMKMT2AMEN1 | |
| SCHEMBL6399384 | 0.86 | LSS (0.51) | LSSKMT2AMEN1 | |
| SCHEMBL5638783 | 0.83 | LSS (0.46) | LSSMAPTKMT2AMEN1 | |
| SCHEMBL6400446 | 0.83 | MAPT (0.54) | LSSLMNAMAPTTP53KMT2A | |
| SCHEMBL5637132 | 0.83 | TP53 (0.49) | LSSMAPTTP53KMT2AMEN1 | |
| SCHEMBL6399382 | 0.82 | LSS (0.55) | LSSMAPTKMT2AMEN1 | |
| SCHEMBL6399304 | 0.82 | LSS (0.55) | LSSMAPTKMT2AMEN1 | |
| SCHEMBL5638888 | 0.82 | LSS (0.53) | LSSKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050020624-A1 | Dihydroindole and tetrahydroquinoline derivatives | AEBI JOHANNES (CH) | 2005-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020624-A1 | Dihydroindole and tetrahydroquinoline derivatives | CYP46A1, LSS, CYP51A1 | LSS 2/4885LMNA 3715/4885MAPT 3562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.